Stoke Therapeutics Grants Options for 245,920 Shares to 18 New Employees

By Public Technologies
  • Stoke Therapeutics granted newly appointed Senior Vice President, Chief Information Officer Stephen Aschettino stock options to purchase 70,000 common shares.
  • Seventeen other new employees received stock options covering 175,920 common shares. All grants took effect October 15, 2026.
  • The options carry an exercise price of $24.61 per share, with 10-year terms under the 2023 Inducement Plan.
  • Vesting spans four years, with 25% vesting on the first anniversary of the applicable vesting commencement date.
  • The remaining shares vest monthly at 1/48 of each award over 36 months. All vesting requires continued employment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610161620BIZWIRE_USPR_____20261016_BW401922) on October 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.